Association of Systemic Immune-inflammation Index With Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study

Yiyang Tang[1], Xiaofang Zeng[1], Yilu Feng[1], Qin Chen[1], Zhenghui Liu[2], Hui Luo[3], Lihuang
Zha[1*] and Zaixin Yu[1,4*]

[1] Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
Republic of China

[2] Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, People's
Republic of China

[3] Department of Cardiovascular Medicine, the First Hospital of Changsha, Changsha, Hunan,
People's Republic of China

[4] National Clinical Research Center for Geriatric Disorders (Xiang Ya), Changsha, Hunan, People's
Republic of China

* Correspondence:
Zaixin Yu
yuzaixin@126.com

Lihuang Zha
zhalihuang@csu.edu.cn

Keywords: congestive heart failure₁, systemic immune-inflammation index₂, mortality₃,
biomarker₄, MIMIC-III₅.

Abstract

Purpose: The present study aimed to clarify the potential predictive significance of Systemic
immune-inflammation index (SII) in assessing the poor prognosis of critically ill patients with
congestive heart failure (CHF).

Methods: Detailed clinical data were extracted from the Multiparameter Intelligent Monitoring in
Intensive Care III database after gaining access and building the local platform. The 30- and 90-day
and hospital all-cause mortalities of the patient was the primary outcome, and the readmission rate
and the occurrence of major cardiovascular adverse events (MACEs) were the secondary outcomes.
the Cox proportional hazard model and Logistic regression analysis were selected to reveal the
relationship between SII level and the research outcome. Further, the propensity score matching
(PSM) analysis was performed to improve the reliability of results by reducing the imbalance across
groups.

Results: There were a total of 4606 subjects who passed the screening process and entered the
subsequent analysis. Multivariate regression analysis showed that after adjusting for possible
confounders, including age, heart rate, and albumin, etc., the high level of SII was independently
associated with 30- and 90-day and hospital mortalities (tertile 3 versus tertile 1: HR, 95% CIs: 1.23,
1.04-1.45; 1.21, 1.06-1.39; 1.26, 1.05-1.50) and the incidence of MACEs (tertile 3 versus tertile 1:
OR, 95% CI: 1.39, 1.12-1.73) in critically ill patients with CHF, but no significant correlation was

found between SII and the readmission rate. Consistently, patients with high SII level still presented
a significantly higher short-term mortality than patients with low SII in the PSM subset.

Conclusion: In critically ill patients with CHF, high level of SII could effectively predict high 30-
and 90-day and hospital mortalities, as well as the high risk of occurrence of MACEs.

1   Introduction

Congestive heart failure (CHF) is defined as a pathological condition in which the cardiac output is
insufficient to maintain the perfusion and metabolic needs of various tissues and organs, mainly
characterized by the congestion of pulmonary circulation, accompanied by the corresponding clinical
manifestations such as shortness of breath and decreased activity tolerance(Sun et al., 2020). CHF is
the severe or terminal stage of most primary cardiovascular diseases and has increasingly become a
major public problem threatening human health. In the United States and Europe, more than 1
million heart failure patients are hospitalized each year, and as the population ages, this number is
expected to increase by more than 50% in the next 15 years(Povsic, 2018). In addition, although
some progress has been made in the treatment in recent years, the prognosis of CHF patients is still
poor, with 5-year mortality rate as high as 40-50%(Chen et al., 2011). Therefore, accurate assessment
and stratification of prognosis are critical to the clinical management of CHF, and the development of
certain prognostic-related biomarkers is also pressing, which can help clinicians to identify high-risk
patients early and take more aggressive treatment measures(Xu et al., 2021).

Although the specific pathogenesis of heart failure remains unclear, abnormal immune activation and
chronic inflammation play an important role. The damage, repair and remodeling of myocardium are
the important link in the occurrence and development of heart failure, of which
immune/inflammatory cells (neutrophils, lymphocytes, etc.) and the inflammatory factors (tumor
necrosis factor, interleukin-6, etc.) released by them are involved(Li et al., 2021). Inflammatory
factors can induce cardiomyocyte hypertrophy, apoptosis and fibrosis, and ultimately lead to adverse
cardiac remodeling and progressive left ventricular dysfunction(Bradham et al., 2002). Inflammatory
factors have been considered to be biomarkers for poor prognosis of heart failure, and anti-
inflammatory therapy is also expected to become a new target for the treatment of heart
failure(Mann, 2015).

Systemic immune-inflammation index (SII) is a composite inflammatory indicator that combines
three significant immune cells, including neutrophil, lymphocyte, and platelet, and is considered to
be an excellent indicator of local immune response and systemic inflammation(Wang et al., 2016).
Neutrophils, platelets and the cytokines they produce are mainly related to non-specific immune
responses, while lymphocytes are considered to be mainly related to specific immune pathways.
Compared with the absolute count of single immune cells, SII has a better representation in reflecting
the inflammation status of the body, with better stability. Until now, SII has been confirmed to be
closely correlated with the poor prognosis of a variety of cardiovascular diseases, including coronary
artery disease(Yang et al., 2020), aortic stenosis(Tosu et al., 2021), infective endocarditis(Agus et al.,
2020), etc., showing good application prospects, but no studies have shown that SII is correlated with
the prognosis of patients with CHF. In view of this, the present study attempted to elucidate the
independent association between SII and the occurrence of adverse events such as short-term
mortality in critically ill patients with CHF, so as to provide reference for the prevention and
treatment of heart failure.

2   Materials and Methods

2.1   Data Sources

All data used in the research and analysis of this study are derived from MIMIC-III (Medical
Information Mart for Intensive Care III) database, a free and open-access large-scale critical care
medicine database developed and run by the Massachusetts Institute of Technology for researchers
all over the world. Another advantage of this database, in addition to including the detailed clinical
data such as demographic data, vital signs, laboratory tests, and various treatment information, is that
it provides accurate death information of all subjects, including time of death in the hospital or within
90 days after discharge, which makes it possible for the clinicians to carry out the prognostic related
research. Besides, since this database has been approved by the local ethics committee as a whole and
the individual identifying information of the research subjects has been deleted, this study no longer
needs additional ethical approval.

2.2   Population Selection and Exclusion

The subjects of this study are all from the MIMIC-III database(Johnson et al., 2016), and patients
who meet all the following requirements are included in the subsequent analysis: (1) Patients
diagnosed with CHF based on the ICD-9 code (code 428.0); (2) Adult patients 18 years of age and
older; (3) First admission to ICU. Patients who met one of the following criteria were excluded from
the study: (1) The length of ICU stay was shorter than 24 hours; (2) Absence of SII results during
hospitalization; (3) Survival time was less than 0 (the time of death of some organ donors may be
earlier than the admission).

2.3   Study Outcomes

The short-term mortality, including the 30- and 90-day and hospital all-cause mortalities of critically
ill patients with CHF, were selected as the primary study outcome, while the secondary study
outcome events were defined as the patients' readmission rate and the occurrence of major adverse
cardiac events (MACEs), which is a composite outcome event, including all-cause death,
readmission for acute heart failure, the use of mechanical circulatory support and the implementation
of heart transplantation(Li et al., 2020).

2.4   Data Extraction and Integration

Through the PostgreSQL software (version 9.6, https://www.postgresql.org/), we extracted detailed
clinical data of the research subjects from the MIMIC-III database, including demographic data (age,
gender, race, etc.), comorbidities (hypertension, diabetes mellitus, atrial fibrillation, etc.), vital signs
(heart rate, blood pressure, respiratory rate, etc.), severity of illness scores (SOFA and SAPSII
scores), laboratory tests (blood routine, electrolytes, etc.) and intervention measures (dialysis,
mechanical ventilation, etc.). And the value of SII is equal to the product of the platelet count and the
neutrophil count divided by the lymphocyte count(Hu et al., 2014).

After separately extracting the required tables from the MIMIC-III database, the Stata software
(version 16, https://www.stata.com/) was used to process and merge these original table and generate
a complete table that can be used for subsequent analysis. Use the "winsorize" function to identify
and process outliers, and fill in missing values through multiple compensation methods.

2.5   Statistical Analyses

The continuous variables were presented in the form of mean ± standard deviation (SD) or median
(interquartile range). If continuous variables satisfy both normal distribution and homogeneity of

variance, t-test was used for analysis, while the Mann-Whitney U test was conducted if the normal
distribution or homogeneity of variance were not satisfied. Categorical variables are expressed in the
form of the number of cases (percentage), with the chi-square test (or Fisher's exact method) for
analysis.

We constructed a generalized additive model (GAM) to determine the non-linear relationship
between SII and 30- and 90-day all-cause mortalities in critically ill patients with CHF. In addition,
we also visually show the relationship between SII and patients' survival through the Kaplan-Meier
(K-M) curve, and use the Log-rank test for hypothesis testing.

In order to relieve the interference of possible confounding factors on the results, we completed
univariate and multivariate regression analysis to further clarify the relationship between SII and
outcome variables. In the crude model, no variables were adjusted. In model I, the age, gender, and
race variables were adjusted, while model II further adjusted other 13 variables on the basis of these
variables of model II, including heart rate, blood urea nitrogen (BUN), albumin, troponin T (cTnT),
N-terminal probrain natriuretic peptide (NT-proBNP), urine output of first day, cardiac index, the
type of first ICU admission, the use of mechanical ventilation and vasopressor, pneumonia, and liver
diseases. The selection of confounding factors follows the following principles(Jaddoe et al., 2014):
(1) A certain factor has an influence of more than 10% on the research variable; (2) Some factors
may have a significant impact on the outcome variable based on past experience. Besides, we used
the variance inflation factor (VIF) to test the multicollinearity between variables with 5 as the
threshold, and the variables with a high degree of collinearity, serum chloride, were deleted to avoid
over-fitting of the model. The Cox regression analysis was used to determine the relationship
between SII and short-term mortalities in critically ill patients with CHF, while Logistic regression
analysis was used to analyze the association between SII and readmission rates or MACEs.

To further enhance the credibility of our analysis, we performed the subgroup analysis and
propensity score matching (PSM) analysis. First, By the subgroup analysis, determine whether the
correlation between the SII and the high 30-day all-cause mortality in critically ill patients with CHF
was consistent across various subgroups stratified mainly by comorbidities, and reflect the stability of
SII as a prognostic marker. The optimal cut-off value of SII for the short-term mortality was
determined by the X-tile (version 3.6.1, Yale University School of Medicine) software, and then the
entire study population was divided into two groups, namely the high SII group and the low SII
group. In this study, all variables with uneven distribution between the two groups of patients were
included in the PSM model as covariates, and the corresponding propensity score was calculated by
Logistic regression. Then the two groups of individuals with similar propensity scores were matched
by 1:1 using nearest neighbor matching method with a caliper width of 0.05, and the histogram of the
propensity score distribution was draw, which was carried out through the Stata software. Then, K-M
curves were depicted and Cox regression analysis was conducted in the matching cohort after PSM,
which further validated SII as an independent risk factor for poor prognosis in the critically ill
patients with CHF.

The statistical analysis above was conducted by EmpowerStats software (version 2.20,
http://www.empowerstats.com/cn/, X&Y solutions, Inc, Boston, MA) and R software (version 3.4.3).
p <0.05 (two-sided) was considered statistically significant.

3   Results

3.1   Clinical Characteristics of Study Subjects

The study subjects were screened according to the process mentioned above, and 4606 subjects were
finally included. The demographic data, vital signs, comorbidities, treatment, scores and laboratory
examinations and other relevant information are shown in Table 1 in detail. In general, the study
subjects included were a little old, with a median age of 74.91 years old, mainly male patients,
reaching 2436, accounting for 52.89%. And the majority of the subjects were whites, accounting for
72.71%, blacks only 7.21%, and other races including Asians accounted for 20.08%. The duration of
follow-up was 90 days, of which 3226 survived and 1380 died due to various reasons before the end
of the study. SII (213.97 vs 163.11, p<0.001) was significantly higher in the non-survivor cohort.
Compared with the survivor group, older patients were identified more frequently in the non-survivor
group, with more unstable vital signs, higher incidence of comorbidities such as VHD, atrial
fibrillation, and renal failure, as well as higher SOFA and SAPSII scores.

3.2   SII Distinguishing a Poor Short-term Prognosis

GAM analysis was used to identify the non-linear correlation between SII and the short-term all-
cause mortality of patients, which showed that there was a U-shaped curve relationship between SII
and 30-day (Figure 1A) and 90-day (Figure 1B) all-cause mortalities in critically ill patients with
CHF, indicating that higher or lower SII may be associated with increased mortality. The K-M
survival curve (Figure 2) also showed that compared with the low SII group, patients with high SII
level had a lower overall survival rate and shorter survival time, with a statistically significant *p*
value.

In order to verify the independent relationship between SII and the poor short-term mortality of CHF
patients, we performed the univariate and multivariate Cox regression analysis (Table 2), with SII
stratified by tertiles. In crude model, the third tertile of SII increased significantly the risk of 30- (HR,
95% CI: 1.73, 1.48-2.03) and 90-day (HR, 95% CI: 1.65, 1.45-1.88) and hospital (HR, 95% CI: 1.61,
1.36-1.91) all-cause mortalities compared with the first tertile. In multivariate model I, after adjusting
for age, sex, and race, the third tertile of SII group also suffered from the higher risk of 30- (HR, 95%
CI: 1.63, 1.40-1.91) and 90-day (HR, 95% CI: 1.57, 1.38-1.79) and hospital (HR, 95% CI: 1.45, 1.22-
1.72) all-cause mortalities. In model II, in addition to adjusting for the variables in model I and other
possible confounders such as pneumonia, the use of dialysis, and BUN level, high levels of SII were
still strongly associated with poor 30- (HR, 95% CI: 1.23, 1.04-1.45) and 90-day (HR, 95% CI: 1.21,
1.06-1.39) and hospital (HR, 95% CI: 1.26, 1.05-1.50) all-cause mortalities.

3.3   Association between SII and Readmission and MACEs

For MACEs, a similar trend was observed. In model II (Table 3), patients with an SII ≥2730.11 were
still at higher incidence of MACEs (OR, 95% CI: 1.39, 1.12-1.73). However, in the multivariate
regression analysis, there was no obvious independent correlation between SII and readmission rate
in the critically ill patients with CHF (tertile 3 versus tertile 1: OR, 95% CI: 0.97, 0.81-1.15).

3.4   Subgroup Analyses

The subgroup analysis was conducted to reveal the correlation between SII and 30-day mortality
across comorbidities and different parameters, and the results were shown in Table 4. First, the
results of the study showed that in all subgroups, the increase in SII level was closely related to the
increase in the 30-day all-cause mortality of critically ill patients with CHF. Besides, most of the
stratification factors have not been found to have a significant impact on the relationship between the
SII and 30-day all-cause mortality (interaction p value>0.05), except for hyperlipemia (*p*=0.006) and
acute myocardial infarction (AMI, *p*= 0.016).

3.5   Prognostic Value of SII After PSM

Determine the optimal cut-off value of SII for 90-day all-cause mortality of critically ill patients with
CHF through X-tile software, which is 5533.4. Subjects were divided into two groups according to
the cut-off value, and their clinical characteristics were summarized in Table 5, most of which were
unevenly distributed across the two groups. In order to effectively balance these confounding factors
and improve the credibility of our results, we conducted a PSM analysis with 1:1 matching. After
PSM, 602 pairs of research objects were generated and the difference of almost all variables were
balanced between the two groups, with a good matching performance (Figure 3). At the same time,
after PSM, compared with the low SII level group, subjects in the high SII level group still
underwent higher 30- (24.9% vs 33.2%, p=0.002) and 90-day (35.0% vs 42.0%, p=0.013) and
hospital (22.4% vs 27.7%, p=0.033) all-cause mortalities, with shorter survival time (Table 5 and
Figure 4). Besides, after adjusting for these covariable in the model II, the increased SII was also
associated with increased risk of short-term all-cause mortality in critically ill patients with CHF after
PSM and the results were shown in Figure 5 in the form of a forest map.

4   Discussion

CHF is widespread all over the world, with gradually increasing incidence with age, and has become
one of the diseases with the highest rates of hospitalizations and deaths in the world, bringing about
enormous medical expenditure and social burden, especially in developing countries(Savarese and
Lund, 2017). In addition to exploring promising treatments, the development of novel prognostic
markers for risk stratification of patients is also of great value for improving the prognosis of
patients. As we all know, as a commonly used indicator of heart failure, NT-proBNP can make a
good performance in prognostic evaluation. However, the clinical applications of NT-proBNP for
risk assessment has some drawbacks and problems. First, compared to the real value, the detection of
NT-proBNP tend to be underestimated because of the short half-life. Moreover, the test of NT-
proBNP may be affected by various factors such as age, gender, and kits(Cho et al., 2020). Therefore,
the search for more possible biomarkers has gradually attracted the attention of researchers and
clinicians.

In the present study, we extracted the clinical data of 4606 critically ill patients who diagnosed with
CHF between 2001 and 2012 in MIMIC-III database, and analyzed the relationship between SII and
short-term prognosis by univariate and multivariate regression analyses for the first time. And the
results have verified that SII could be an independent biomarker for poor short-term prognosis of
CHF. There was a nonlinear relationship between SII and 30- and 90-day mortalities. And the higher
SII level, the higher risk of 30- and 90-day and hospital mortalities, as well as the higher incidence of
MACEs. The correlation remained significant after adjusting for possible confounders, stratifying
according to comorbidities, and PSM matching, respectively.

Inflammation, a widely accepted hallmark of heart failure, has been proven to play an indispensable
role in the pathogenesis of heart failure(Dick and Epelman, 2016). The increase and activation of
inflammation-related cytokines not only present a reflection of the activation of inflammation in
vivo, but have also been identified as being associated with poor prognosis in heart failure. Tumor
necrosis factor α (TNF-α) was the first cytokine found to be significantly elevated in the serum of
patients with heart failure, which could directly induce myocardial apoptosis and necrosis, bringing
about ventricular adverse remodeling(Anker and von Haehling, 2004). The elevated levels of TNF-α
often indicated impaired cardiac systolic function and poor long-term survival(Rauchhaus et al.,
2000). In addition, interleukin 6 (IL-6), another classic cytokine mainly derived from monocytes,

could be significantly increased in patients with left ventricular systolic dysfunction without clinical
symptoms, and may be a sensitive indicator for the early diagnosis of heart failure(Plenz et al., 2001).
IL-6 was also positively correlated with the severity of heart failure, the concentration of which was
negatively correlated with left ventricular ejection fraction and overall survival(Markousis-
Mavrogenis et al., 2019). Although these inflammatory molecules had good performance in the
prognostic evaluation of patients, the expensive detection cost limited their clinical application. As a
novel biomarker, SII can systematically and comprehensively reflect the status of inflammation in
vivo. Blood routine is a routine examination for almost all hospitalized patients. It is simple, fast, and
inexpensive. Compared with NT-proBNP, cytokines and other prognostic indicators, SII can
effectively screen high-risk patients, guide the formulation of individualized treatment plans and
improve the prognosis of patients without additional cost, with a broad application prospect,
especially in underdeveloped areas.

The mechanisms of the relationship between SII and adverse prognosis of CHF remains unclear, and
possible explanations are as follows. Recently, it has been revealed that circulating immune cells and
their subtypes had a vital indicative effect on the prognosis of cardiovascular diseases(Strassheim et
al., 2019). SII was a prognostic indicator that integrates three circulating immune cells, including
neutrophils, lymphocytes, and platelets, the increase of which indicates either a relative increase in
platelets and neutrophils counts or a relative decrease in lymphocytes. Neutrophils are the main
component of white blood cells, accounting for 60-70% of the total, and play an important role in the
non-specific immune system. In the inflammatory response, neutrophils react rapidly, with strong
chemotaxis and phagocytosis, and participate in the progression of various cardiovascular diseases,
including heart failure(Bonaventura et al., 2019). In addition, neutrophils could contribute to
oxidative stress and endothelial dysfunction by releasing a large amount of myeloperoxidase,
NADPH oxidase, and so on(Swirski and Nahrendorf, 2013). According to a community-based
study(Arruda-Olson et al., 2009), absolute neutrophils can effectively predict the increased incidence
of acute decompensated heart failure after AMI, and it was also an independent risk factor for
death(Uthamalingam et al., 2011). Lymphocytes mainly consist of two subtype including T and B
cells, which were often associated with the specific immunity. Several previous studies have reported
that lymphocyte counts in patients with heart failure were lower than in the normal population and
lymphopenia served as an independent predictor of poor survival of patients with chronic and
advanced heart failure(Charach et al., 2011; Vaduganathan et al., 2012). Lymphopenia was
considered to be an important feature of systemic inflammation, which may be caused by the
following mechanisms. First, the circulating lymphocytes were attracted into the cardiac tissue,
leading to its redistribution. Then, lymphopenia was related to the activation of renin-angiotensin-
aldosterone hormone and the adrenergic nervous system, which could exert pro-apoptotic effects on
lymphocytes(Charach et al., 2011). Platelets were differentiated from the mononuclear-phagocyte
system and were the key mediator linking the two pathological processes of inflammation and
thrombosis(Ye et al., 2019). On the one hand, platelets were the main effector molecules for
hemostasis after cardiovascular injury. On the other hand, the activation of platelets plays a major
role in pathogenic thrombosis and participates in the pathogenesis of many groups of cardiovascular
diseases, including coronary heart disease(Glezeva et al., 2016). Moreover, Platelets interacted with
leukocytes and their subtypes (neutrophil, lymphocytes, etc.) and endothelial cells and activated
them, inducing monocyte adhesion and transport, releasing inflammatory factors such as TNF-α and
IL-1, which together promoted local inflammation and fibrosis in heart failure(Glezeva et al., 2016).
The study by Kandis(Kandis et al., 2011) et al. demonstrated that mean platelet volume (MPV),
indicating the activation of platelets, increased significantly in decompensated heart failure patients.
In addition, MPV at admission was independently associated with the hospital and 6-month
mortalities.

Besides, the subgroup analysis was also conducted, and the results demonstrated that the association
was stable and consistent between the high level of SII and the poor 30-day mortality across CHF
patients with different comorbidities or severity scores. We also noted that, among the critically ill
patients with CHF, patients complicated with AMI and hyperlipidemia had a higher risk of 30-day
mortality, and this risk was higher for higher SII, which implied that SII may be more valuable for
the prognostic evaluation of CHF patients with AMI or hyperlipidemia. Similarly, the previous study
has also shown that in patients with coronary heart disease, the high level of SII indicated a high risk
of cardiac death in the future, as well as the high incidence of non-fatal stroke and heart failure(Yang
et al., 2020). Although there was no research on the correlation between SII and hyperlipidemia, the
interconnection of hyperlipidemia and inflammation involved in the pathogenesis of cardiovascular
disease has been recognized(Rodriguez-Garcia and Alcaide, 2021).

As a retrospective cohort study, the existence of confounding factors cannot be ignored, and it was
difficult to intuitively and accurately judge the correlation between SII level and the prognosis of
CHF patients. Another highlight of this study was the use of PSM analysis to reduce the imbalance of
confounding factors across different groups. After PSM, the most baseline characteristics were well-
balanced between these two groups, except for the use of dialysis, the type of first ICU admission,
and the peripheral vascular diseases. More importantly, the conclusion that high levels of SII were
independently related to high short-term mortality remained stand before and after PSM, which
improved the reliability of SII as a prognostic marker of CHF.

But at the same time, there were certain limitations in this study. First, the present study was
conducted at a single center and did not validate the prognostic value of SII in a validation cohort.
Second, the clinical data were collected retrospectively from databases and it was difficult to ensure
that variables were evenly distributed across groups, although multiple regression models were
conducted to adjust for confounders and PSM analysis was used to minimize inter-group differences
in baseline characteristics. Third, some significant variables may be omissive due to the lack of data.
Last, this study was unable to determine the underlying mechanism of the association between high
SII and poor prognosis of CHF patients, and further experiments are necessary.

5 Conclusion

In summary, the high level of SII is closely related to the poor short-term prognosis in critically ill
patients with CHF, including 30- and 90-day and hospital all-cause mortalities, as well as the
occurrence of MACEs, and is expected to be a simple and effective prognostic evaluation indicator.

6 Conflict of Interest

All authors declare that there is no conflict of interest.

7 Author Contributions

Zaixin Yu and Lihuang Zha are the senior author who conceived and designed the study. Yiyang
Tang and Xiaofang Zeng collected and analyzed the clinical data. Yiyang Tang drafted the
manuscript. Yilu Feng and Qin Chen participated in the implementation of statistical methods in this
study and put forward constructive suggestions. Zhenghui Liu and Hui Luo reviewed the study and
participated in the interpretation of the results. All authors gave final approval of the version to be
published, and agree to be accountable for all aspects of the work.

8 Funding

Our study was supported by the National Natural Science Foundation of China (81873416), the Key
Research and Development Program of Hunan Province (2020SK2065) and Natural Science
Foundation Project of Hunan Province (2020JJ4634).

9   Data availability

Publicly available datasets were analyzed in this study. This data can be extracted from Monitoring in
Intensive Care Database III version 1.4 (MIMIC-III v.1.4) after passing on the required courses and
obtaining the authorization.

Reference styles

Agus, H.Z., Kahraman, S., Arslan, C., Yildirim, C., Erturk, M., Kalkan, A.K., et al. (2020). Systemic
348   immune-inflammation index predicts mortality in infective endocarditis. *J Saudi Heart Assoc*
349   32(1)**,** 58-64. doi: 10.37616/2212-5043.1010.

350   Anker, S.D., and von Haehling, S. (2004). Inflammatory mediators in chronic heart failure: an
351   overview. *Heart* 90(4)**,** 464-470. doi: 10.1136/hrt.2002.007005.

352   Arruda-Olson, A.M., Reeder, G.S., Bell, M.R., Weston, S.A., and Roger, V.L. (2009). Neutrophilia
353   predicts death and heart failure after myocardial infarction: a community-based study. *Circ*
354   *Cardiovasc Qual Outcomes* 2(6)**,** 656-662. doi: 10.1161/CIRCOUTCOMES.108.831024.

355   Bonaventura, A., Montecucco, F., Dallegri, F., Carbone, F., Luscher, T.F., Camici, G.G., et al.
356   (2019). Novel findings in neutrophil biology and their impact on cardiovascular disease.
357   *Cardiovasc Res* 115(8)**,** 1266-1285. doi: 10.1093/cvr/cvz084.

358   Bradham, W.S., Bozkurt, B., Gunasinghe, H., Mann, D., and Spinale, F.G. (2002). Tumor necrosis
359   factor-alpha and myocardial remodeling in progression of heart failure: a current perspective.
360   *Cardiovasc Res* 53(4)**,** 822-830. doi: 10.1016/s0008-6363(01)00503-x.

361   Charach, G., Grosskopf, I., Roth, A., Afek, A., Wexler, D., Sheps, D., et al. (2011). Usefulness of
362   total lymphocyte count as predictor of outcome in patients with chronic heart failure. *Am J*
363   *Cardiol* 107(9)**,** 1353-1356. doi: 10.1016/j.amjcard.2010.12.049.

364   Chen, J., Normand, S.L., Wang, Y., and Krumholz, H.M. (2011). National and regional trends in
365   heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. *JAMA*
366   306(15)**,** 1669-1678. doi: 10.1001/jama.2011.1474.

367   Cho, J.H., Cho, H.J., Lee, H.Y., Ki, Y.J., Jeon, E.S., Hwang, K.K., et al. (2020). Neutrophil-
368   Lymphocyte Ratio in Patients with Acute Heart Failure Predicts In-Hospital and Long-Term
369   Mortality. *J Clin Med* 9(2). doi: 10.3390/jcm9020557.

370   Dick, S.A., and Epelman, S. (2016). Chronic Heart Failure and Inflammation: What Do We Really
371   Know? *Circ Res* 119(1)**,** 159-176. doi: 10.1161/CIRCRESAHA.116.308030.

372   Glezeva, N., Gilmer, J.F., Watson, C.J., and Ledwidge, M. (2016). A Central Role for Monocyte-
373   Platelet Interactions in Heart Failure. *J Cardiovasc Pharmacol Ther* 21(3)**,** 245-261. doi:
374   10.1177/1074248415609436.

375   Hu, B., Yang, X.R., Xu, Y., Sun, Y.F., Sun, C., Guo, W., et al. (2014). Systemic immune-
376   inflammation index predicts prognosis of patients after curative resection for hepatocellular
377   carcinoma. *Clin Cancer Res* 20(23)**,** 6212-6222. doi: 10.1158/1078-0432.CCR-14-0442.

Jaddoe, V.W., de Jonge, L.L., Hofman, A., Franco, O.H., Steegers, E.A., and Gaillard, R. (2014).
First trimester fetal growth restriction and cardiovascular risk factors in school age children:
population based cohort study. *BMJ* 348**,** g14. doi: 10.1136/bmj.g14.

Johnson, A.E., Pollard, T.J., Shen, L., Lehman, L.W., Feng, M., Ghassemi, M., et al. (2016). MIMIC-
III, a freely accessible critical care database. *Sci Data* 3**,** 160035. doi: 10.1038/sdata.2016.35.

Kandis, H., Ozhan, H., Ordu, S., Erden, I., Caglar, O., Basar, C., et al. (2011). The prognostic value
of mean platelet volume in decompensated heart failure. *Emerg Med J* 28(7)**,** 575-578. doi:
10.1136/emj.2009.088401.

Li, H., Chen, C., and Wang, D.W. (2021). Inflammatory Cytokines, Immune Cells, and Organ
Interactions in Heart Failure. *Front Physiol* 12**,** 695047. doi: 10.3389/fphys.2021.695047.

Li, W., Huang, A., Zhu, H., Liu, X., Huang, X., Huang, Y., et al. (2020). Gut microbiota-derived
trimethylamine N-oxide is associated with poor prognosis in patients with heart failure. *Med J*
Aust 213(8)**,** 374-379. doi: 10.5694/mja2.50781.

Mann, D.L. (2015). Innate immunity and the failing heart: the cytokine hypothesis revisited. *Circ Res*
116(7)**,** 1254-1268. doi: 10.1161/CIRCRESAHA.116.302317.

Markousis-Mavrogenis, G., Tromp, J., Ouwerkerk, W., Devalaraja, M., Anker, S.D., Cleland, J.G., et
al. (2019). The clinical significance of interleukin-6 in heart failure: results from the
BIOSTAT-CHF study. *Eur J Heart Fail* 21(8)**,** 965-973. doi: 10.1002/ejhf.1482.

Plenz, G., Song, Z.F., Tjan, T.D., Koenig, C., Baba, H.A., Erren, M., et al. (2001). Activation of the
cardiac interleukin-6 system in advanced heart failure. *Eur J Heart Fail* 3(4)**,** 415-421. doi:
10.1016/s1388-9842(01)00137-4.

Povsic, T.J. (2018). Emerging Therapies for Congestive Heart Failure. *Clin Pharmacol Ther* 103(1)**,**
77-87. doi: 10.1002/cpt.913.

Rauchhaus, M., Doehner, W., Francis, D.P., Davos, C., Kemp, M., Liebenthal, C., et al. (2000).
Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation*
102(25)**,** 3060-3067. doi: 10.1161/01.cir.102.25.3060.

Rodriguez-Garcia, M., and Alcaide, P. (2021). Vascular Inflammation and Hyperlipidemia: The
Neutrophil Within. *JACC Basic Transl Sci* 6(6)**,** 524-526. doi: 10.1016/j.jacbts.2021.05.006.

Savarese, G., and Lund, L.H. (2017). Global Public Health Burden of Heart Failure. *Card Fail Rev*
3(1)**,** 7-11. doi: 10.15420/cfr.2016:25:2.

Strassheim, D., Dempsey, E.C., Gerasimovskaya, E., Stenmark, K., and Karoor, V. (2019). Role of
Inflammatory Cell Subtypes in Heart Failure. *J Immunol Res* 2019**,** 2164017. doi:
10.1155/2019/2164017.

Sun, D., Zhang, F., Ma, T., Zhang, Y., and Liang, Z. (2020). Atorvastatin alleviates left ventricular
remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho
kinase signaling pathway. *Pharmacol Rep* 72(4)**,** 903-911. doi: 10.1007/s43440-020-00085-3.

Swirski, F.K., and Nahrendorf, M. (2013). Leukocyte behavior in atherosclerosis, myocardial
infarction, and heart failure. *Science* 339(6116)**,** 161-166. doi: 10.1126/science.1230719.

Tosu, A.R., Kalyoncuoglu, M., Biter, H.I., Cakal, S., Selcuk, M., Cinar, T., et al. (2021). Prognostic
Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and
Mortality in Severe Aortic Stenosis Patients after TAVI. *Medicina (Kaunas)* 57(6). doi:
10.3390/medicina57060588.

Uthamalingam, S., Patvardhan, E.A., Subramanian, S., Ahmed, W., Martin, W., Daley, M., et al.
(2011). Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in
acute decompensated heart failure. *Am J Cardiol* 107(3)**,** 433-438. doi:
10.1016/j.amjcard.2010.09.039.

Vaduganathan, M., Ambrosy, A.P., Greene, S.J., Mentz, R.J., Subacius, H.P., Maggioni, A.P., et al.
(2012). Predictive value of low relative lymphocyte count in patients hospitalized for heart
failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail* 5(6)**,**
750-758. doi: 10.1161/CIRCHEARTFAILURE.112.970525.

Wang, B.L., Tian, L., Gao, X.H., Ma, X.L., Wu, J., Zhang, C.Y., et al. (2016). Dynamic change of
the systemic immune inflammation index predicts the prognosis of patients with
hepatocellular carcinoma after curative resection. *Clin Chem Lab Med* 54(12)**,** 1963-1969.
doi: 10.1515/cclm-2015-1191.

Xu, M., Zhang, L., Song, S., Pan, L., Muhammad Arslan, I., Chen, Y., et al. (2021). Hydrogen
sulfide: Recent progress and perspectives for the treatment of dermatological diseases. *J Adv*
Res 27**,** 11-17. doi: 10.1016/j.jare.2020.02.003.

Yang, Y.L., Wu, C.H., Hsu, P.F., Chen, S.C., Huang, S.S., Chan, W.L., et al. (2020). Systemic
immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery
disease. *Eur J Clin Invest* 50(5)**,** e13230. doi: 10.1111/eci.13230.

Ye, G.L., Chen, Q., Chen, X., Liu, Y.Y., Yin, T.T., Meng, Q.H., et al. (2019). The prognostic role of
platelet-to-lymphocyte ratio in patients with acute heart failure: A cohort study. *Sci Rep* 9(1)**,**
10639. doi: 10.1038/s41598-019-47143-2.

Figure 1. The non-linear curve fitting of the association between SII and 30- (A) and 90- (B) day all-
cause mortalities in critically ill patients with CHF after adjusting for age, gender, race, and other
potential variables. SII, systemic immune-inflammation index. CHF, congestive heart failure.

Figure 2. Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
stratified by SII tertile in critically ill patients with CHF. SII, systemic immune-inflammation index.
CHF, congestive heart failure.

Figure 3. The histogram presenting the range of propensity scores and the corresponding number of
matches in high (red) and low (blue) SII groups. SII, systemic immune-inflammation index.

Figure 4. Kaplan-Meier survival curves showing the 30- (A) and 90- (B) day all-cause mortalities
stratified by cut-off value of SII in critically ill patients with CHF before PSM. C and D presented the
correlation between SII and 30- and 90-day mortalities after PSM, separately. SII, systemic immune-
inflammation index. CHF, congestive heart failure. PSM, propensity score matching.

Figure 5. The forest plot showing the univariate (A) and multivariate (B) Cox regression for effects
of SII on short-term mortality in the critically ill patients with CHF before and after PSM. SII,
systemic immune-inflammation index. CHF, congestive heart failure. PSM, propensity score
matching.

A

Univariate analysis	p value	HR(95%CI)
Before PSM		
30−day mortality	<0.0001	1.8841(1.6145, 2.1986)
90−day mortality	<0.0001	1.7045(1.4893, 1.9508)
Hospital mortality	<0.0001	1.7299(1.4624, 2.0463)
After PSM		
30−day mortality	0.0014	1.4108(1.1416, 1.7435)
90−day mortality	0.0075	1.2829(1.0686, 1.5402)
Hospital mortality	0.0019	1.4352(1.1423, 1.8033)

B

Multivariate analysis	p value	HR(95%CI)
Before PSM		
30−day mortality	<0.0001	1.3930(1.1887, 1.6323)
90−day mortality	0.0003	1.2923(1.1254, 1.4840)
Hospital mortality	0.0004	1.3652(1.1486, 1.6226)
After PSM		
30−day mortality	0.0021	1.4018(1.1306, 1.7380)
90−day mortality	0.0068	1.2917(1.0730, 1.5550)
Hospital mortality	0.0167	1.3276(1.0526, 1.6745)

483   **Table 1.** The baseline clinical characteristics of critically ill patients with CHF.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	*p* value
Demographics				
Age, years	74.91 (64.06-83.07)	72.70 (61.97-81.65)	78.94 (69.40-84.82)	<0.001
Male, n (%)	2436 (52.89%)	1690 (52.39%)	746 (54.06%)	0.298
Ethnicity, n (%)				<0.001
White	3349 (72.71%)	2361 (73.19%)	988 (71.59%)	
Black	332 (7.21%)	254 (7.87%)	78 (5.65%)	
Others	925 (20.08%)	611 (18.94%)	314 (22.75%)	
Vital signs				
HR, beats/minute	85.02 (74.53-96.54)	84.33 (74.33-95.77)	86.67 (75.24-98.65)	<0.001
RR, times/minute	19.42 (16.87-22.38)	19.17 (16.76-21.91)	20.03 (17.24-23.45)	<0.001
SBP, mmHg	113.64 (104.46-125.96)	114.89 (105.50-126.98)	111.04 (101.60-123.48)	<0.001
DBP, mmHg	56.93 (50.87-63.71)	57.85 (51.64-64.34)	55.10 (49.46-61.64)	<0.001
Temperature, ℃	36.76 (36.37-37.21)	36.80 (36.42-37.22)	36.65 (36.26-37.13)	<0.001
SpO2, %	97.23 (95.74-98.46)	97.25 (95.81-98.49)	97.19 (95.52-98.40)	0.018
Weight, kg	77.75 (64.70-93.60)	79.80 (65.60-96.00)	73.80 (62.00-88.00)	<0.001
Therapies, n (%)				
ACEI	1266 (27.49%)	1012 (31.37%)	254 (18.41%)	<0.001
ARB	183 (3.97%)	151 (4.68%)	32 (2.32%)	<0.001
β-blocker	2827 (61.38%)	2074 (64.29%)	753 (54.57%)	<0.001
Digoxin	475 (10.31%)	303 (9.39%)	172 (12.46%)	0.002
Furosemide	3190 (69.26%)	2275 (70.52%)	915 (66.30%)	0.004
Statins	1451 (31.50%)	1121 (34.75%)	330 (23.91%)	<0.001
Dialysis	478 (10.38%)	278 (8.62%)	200 (14.49%)	<0.001
Vasopressor	1234 (26.79%)	727 (22.54%)	507 (36.74%)	<0.001
Ventilation	1879 (40.79%)	1133 (35.12%)	746 (54.06%)	<0.001
Assisted circulation	282 (6.12%)	186 (5.77%)	96 (6.96%)	0.123

484   **Table 1.** Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	p value
Laboratory events				
Hemoglobin, g/dl	10.90 (9.70-12.30)	11.10 (9.80-12.50)	10.70 (9.40-11.90)	<0.001
Creatinine, mg/dl	1.20 (0.90-1.80)	1.20 (0.90-1.70)	1.30 (0.90-2.10)	<0.001
BUN, mg/dl	27.00 (18.00-43.00)	25.00 (17.00-40.00)	33.00 (21.00-51.00)	<0.001
Glucose, mg/dl	135.33 (115.00-166.12)	134.23 (115.47-164.03)	137.71 (114.36-170.52)	0.111
Sodium, mmol/L	139.00 (136.00-141.00)	139.00 (136.00-141.00)	138.00 (135.00-141.00)	0.023
Potassium, mmol/L	4.20 (3.80-4.60)	4.10 (3.70-4.60)	4.20 (3.80-4.70)	0.002
Chloride, mmol/L	103.00 (99.00-107.00)	103.00 (99.25-107.00)	103.00 (99.00-107.00)	0.035
Bicarbonate, mmol/L	24.00 (21.00-28.00)	25.00 (22.00-28.00)	24.00 (20.00-27.00)	<0.001
PT, second	14.30 (13.20-16.80)	14.20 (13.10-16.50)	14.80 (13.40-17.90)	<0.001
APTT, second	31.80 (27.30-40.40)	31.30 (27.10-40.20)	32.70 (27.87-41.10)	0.001
Lactate, mmol/L	1.82 (1.30-2.90)	1.80 (1.20-2.83)	2.00 (1.30-3.00)	<0.001
Albumin, g/dL	3.00 (2.56-3.40)	3.00 (2.60-3.42)	2.89 (2.45-3.24)	<0.001
Bilirubin, mg/dL	1.40 (0.60-3.05)	1.40 (0.60-3.00)	1.41 (0.60-3.10)	0.339
ALT, IU/L	60.00 (22.00-298.33)	69.00 (23.92-327.15)	45.00 (19.00-207.75)	<0.001
NT-proBNP, ng/ml	10.98 (4.67-18.83)	10.70 (4.26-18.34)	11.91 (5.67-19.96)	<0.001
cTnT, ng/mL	1.34 (0.10-2.87)	1.46 (0.11-2.94)	1.12 (0.09-2.58)	<0.001
CI, L/min/m^2	2.76 (2.13-3.47)	2.75 (2.13-3.48)	2.78 (2.14-3.45)	0.626
Urine output, L	1.54 (0.89-2.44)	1.73 (1.02-2.65)	1.14 (0.67-1.87)	<0.001
SII ×10	174.76 (92.24-344.55)	163.11 (88.62-309.02)	213.97 (105.80-430.34)	<0.001
Hospitalization type				<0.001
Emergency, n (%)	4062 (88.19%)	2804 (86.92%)	1258 (91.16%)	
Elective, n (%)	367 (7.97%)	300 (9.30%)	67 (4.86%)	
First ICU admission				<0.001
CCU, n (%)	1236 (26.83%)	898 (27.84%)	338 (24.49%)	
MICU, n (%)	2005 (43.53%)	1308 (40.55%)	697 (50.51%)	

485   **Table 1.** Continued.

Parameter	All(n=4606)	Survivors (n=3226)	Non-survivors (n=1380)	p value
Comorbidities, n (%)				
Hypertension	937 (20.34%)	655 (20.30%)	282 (20.43%)	0.919
Hyperlipemia	1260 (27.36%)	975 (30.22%)	285 (20.65%)	<0.001
Diabetes mellitus	1657 (35.97%)	1218 (37.76%)	439 (31.81%)	<0.001
Atrial fibrillation	2077 (45.09%)	1361 (42.19%)	716 (51.88%)	<0.001
AMI	346 (7.51%)	241 (7.47%)	105 (7.61%)	0.871
VHD	463 (10.05%)	289 (8.96%)	174 (12.61%)	<0.001
Peripheral vascular	577 (12.53%)	397 (12.31%)	180 (13.04%)	0.489
Pulmonary circulation	292 (6.34%)	183 (5.67%)	109 (7.90%)	0.005
Pneumonia	1350 (29.31%)	858 (26.60%)	492 (35.65%)	<0.001
COPD	245 (5.32%)	156 (4.84%)	89 (6.45%)	0.025
Liver diseases	232 (5.04%)	138 (4.28%)	94 (6.81%)	<0.001
Renal failure	1120 (24.32%)	757 (23.47%)	363 (26.30%)	0.040
Stroke	250 (5.43%)	148 (4.59%)	102 (7.39%)	<0.001
Hypothyroidism	555 (12.05%)	392 (12.15%)	163 (11.81%)	0.746
Malignancy	253 (5.49%)	128 (3.97%)	125 (9.06%)	<0.001
Depression	359 (7.79%)	276 (8.56%)	83 (6.01%)	0.003
Scores				
SOFA	5.00 (3.00-7.00)	4.00 (3.00-6.00)	6.00 (4.00-8.00)	<0.001
SAPSII	40.00 (32.00-49.00)	38.00 (30.00-46.00)	47.00 (39.00-56.00)	<0.001
Length of ICU stay, h	94.00 (50.00-187.00)	88.00 (48.00-166.75)	122.00 (62.00-240.25)	<0.001

Abbreviations: HR, heart rate; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic
blood pressure; SpO2, percutaneous oxygen saturation; ACEI, angiotensin-converting enzyme
inhibitors; ARB, angiotensin receptor blockers; BUN, blood urea nitrogen; PT, prothrombin time;
APTT, activated partial thromboplastin time; ALT, alanine transaminase; cTnT, troponin T; NT-
proBNP, N-terminal pro brain natriuretic peptide; CI, cardiac index; SII, Systemic immune-
inflammation index; CHF, congestive heart failure; AMI, acute myocardial infarction; VHD, valvular
heart disease; COPD, chronic obstructive pulmonary disease. CCU, cardiac care unit; MICU, medical
intensive care unit.

Table 2. The univariate and multivariate Cox regression analysis exploring the association of SII
tertile with short-term mortality of critically ill patients with CHF.

	Crude		Model I		Model II	
	HR (95%CIs)	*P* value	HR (95%CIs)	*P* value	HR (95%CIs)	*P* value
30-day all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	<0.0001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.17 (0.99, 1.38)	0.067	1.14 (0.97, 1.35)	0.112	1.05 (0.89, 1.25)	0.524
≥2730.11	1.73 (1.48, 2.03)	<0.001	1.63 (1.40, 1.91)	<0.001	1.23 (1.04, 1.45)	0.011
P for trend	<0.001		<0.001		<0.001	
90-day all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	0.001
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.12 (0.97, 1.28)	0.114	1.10 (0.96, 1.27)	0.168	1.02 (0.88, 1.17)	0.820
≥2730.11	1.65 (1.45, 1.88)	<0.001	1.57 (1.38, 1.79)	<0.001	1.21 (1.06, 1.39)	0.005
P for trend	<0.001		<0.001		<0.001	
Hospital all-cause mortality						
SII	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.0001	1.00 (1.00, 1.00)	0.002
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.27 (1.06, 1.52)	0.008	1.21 (1.01, 1.45)	0.035	1.17 (0.97, 1.40)	0.096
≥2730.11	1.61 (1.36, 1.91)	<0.001	1.45 (1.22, 1.72)	<0.001	1.26 (1.05, 1.50)	0.011
P for trend	<0.001		<0.001		<0.001	

Crude model was adjusted for none.
Model I was adjusted for age, gender, and race.
Model II was adjusted for age, gender, race, heart rate, blood urea nitrogen, albumin, troponin T, NT-
proBNP, urine output of first day, cardiac index, the type of first ICU admission, the use of
mechanical ventilation and vasopressor, pneumonia, and liver diseases.
Abbreviations: SII, Systemic immune-inflammation index; CHF, congestive heart failure; HR,
hazard ratio; CI, confidence interval.

Table 3. The univariate and multivariate Logistic regression analysis exploring the association of SII
tertile with readmission and MACEs of critically ill patients with CHF.

	Crude		Model I		Model II	
	OR (95%CIs)	*P* value	OR (95%CIs)	*P* value	OR (95%CIs)	*P* value
Readmission						
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	0.91 (0.77, 1.07)	0.253	0.94 (0.80, 1.11)	0.472	0.94 (0.80, 1.11)	0.484
≥2730.11	0.88 (0.75, 1.04)	0.129	0.93 (0.78, 1.10)	0.392	0.97 (0.81, 1.15)	0.703
P for trend	<0.001		<0.001		<0.001	
MACEs						
SII (tertile)						
<1144.28	1 (ref)		1 (ref)		1 (ref)	
≥1144.28, <2730.11	1.17 (1.02, 1.35)	0.030	1.17 (1.02, 1.35)	0.028	0.92 (0.74, 1.13)	0.417
≥2730.11	2.01 (1.73, 2.32)	<0.001	2.02 (1.74, 2.35)	<0.001	1.39 (1.12, 1.73)	0.003
P for trend	<0.001		<0.001		<0.001	

Crude model was adjusted for none.
Model I was adjusted for age, gender, and race.
Model II was adjusted for age, gender, race, heart rate, blood urea nitrogen, albumin, troponin T, NT-
proBNP, urine output of first day, cardiac index, the type of first ICU admission, the use of
mechanical ventilation and vasopressor, pneumonia, and liver diseases.
Abbreviations: SII, Systemic immune-inflammation index; CHF, congestive heart failure; HR,
hazard ratio; CI, confidence interval.

520 **Table 4.** Subgroup analysis of the relationship between SII and 30-day all-cause mortality.

	N	SII			*P* for interaction
		<1144.28	≥1144.28, <2730.11	≥2730.11	
Hypertension					0.178
No	3669	1.0 (ref)	1.09 (0.90, 1.31)	1.70 (1.44, 2.02)	
Yes	937	1.0 (ref)	1.57 (1.07, 2.31)	1.88 (1.28, 2.76)	
Diabetes					0.384
No	2949	1.0 (ref)	1.16 (0.95, 1.42)	1.62 (1.34, 1.95)	
Yes	1657	1.0 (ref)	1.22 (0.90, 1.65)	2.01 (1.52, 2.67)	
Hyperlipemia					0.006
No	3346	1.0 (ref)	1.13 (0.94, 1.36)	1.51 (1.27, 1.80)	
Yes	1260	1.0 (ref)	1.40 (0.96, 2.05)	2.77 (1.94, 3.96)	
AMI					0.016
No	4260	1.0 (ref)	1.09 (0.92, 1.30)	1.71 (1.46, 2.01)	
Yes	346	1.0 (ref)	2.63 (1.30, 5.30)	2.31 (1.14, 4.69)	
VHD					0.602
No	4143	1.0 (ref)	1.15 (0.96, 1.38)	1.76 (1.49, 2.07)	
Yes	463	1.0 (ref)	1.23 (0.76, 2.00)	1.50 (0.94, 2.41)	
PCD					0.931
No	4314	1.0 (ref)	1.17 (0.98, 1.39)	1.72 (1.46, 2.02)	
Yes	292	1.0 (ref)	1.15 (0.61, 2.19)	1.86 (1.05, 3.32)	
Atrial fibrillation					0.437
No	2529	1.0 (ref)	1.04 (0.82, 1.31)	1.59 (1.28, 1.98)	
Yes	2077	1.0 (ref)	1.29 (1.02, 1.64)	1.84 (1.47, 2.31)	
Pneumonia					0.061
No	3256	1.0 (ref)	1.18 (0.96, 1.44)	1.89 (1.56, 2.29)	
Yes	1350	1.0 (ref)	1.09 (0.82, 1.45)	1.33 (1.03, 1.74)	
COPD					0.962
No	4361	1.0 (ref)	1.16 (0.98, 1.38)	1.72 (1.47, 2.02)	
Yes	245	1.0 (ref)	1.32 (0.54, 3.20)	1.86 (0.83, 4.17)	
Liver diseases					0.065
No	4374	1.0 (ref)	1.26 (1.06, 1.50)	1.85 (1.57, 2.18)	
Yes	232	1.0 (ref)	0.62 (0.34, 1.13)	1.24 (0.70, 2.21)	

521   **Table 4.** Continued.

	N	SII			*P* for interaction
		<1144.28	≥1144.28, <2730.11	≥2730.11	
Renal failure					0.396
No	3486	1.0 (ref)	1.10 (0.91, 1.33)	1.72 (1.44, 2.05)	
Yes	1120	1.0 (ref)	1.39 (1.00, 1.94)	1.79 (1.30, 2.48)	
Hypothyroidism					0.628
No	4051	1.0 (ref)	1.13 (0.95, 1.35)	1.71 (1.45, 2.01)	
Yes	555	1.0 (ref)	1.46 (0.90, 2.38)	1.96 (1.23, 3.12)	
Stroke					0.618
No	4356	1.0 (ref)	1.14 (0.96, 1.36)	1.69 (1.44, 1.99)	
Yes	250	1.0 (ref)	1.45 (0.79, 2.65)	2.24 (1.26, 3.97)	
Depression					0.216
No	4247	1.0 (ref)	1.17 (0.98, 1.39)	1.79 (1.52, 2.10)	
Yes	359	1.0 (ref)	1.11 (0.55, 2.25)	1.02 (0.51, 2.03)	
Malignancy					0.879
No	4353	1.0 (ref)	1.18 (0.99, 1.40)	1.72 (1.46, 2.02)	
Yes	253	1.0 (ref)	1.02 (0.57, 1.83)	1.57 (0.94, 2.63)	
SOFA					0.172
<5	2149	1.0 (ref)	1.24 (0.91, 1.70)	2.21 (1.66, 2.96)	
≥5	2457	1.0 (ref)	1.20 (0.99, 1.46)	1.58 (1.31, 1.90)	
SAPSII					0.255
<40	2181	1.0 (ref)	1.22 (0.87, 1.71)	1.99 (1.43, 2.75)	
≥40	2425	1.0 (ref)	1.13 (0.93, 1.37)	1.42 (1.19, 1.69)	

522   Abbreviations: SII, Systemic immune-inflammation index; AMI, acute myocardial infarction; VHD,
523   valvular heart disease; PCD, peripheral vascular diseases; COPD, chronic obstructive pulmonary
524   disease.

530 **Table 5. The clinical characteristics in critically ill patients with CHF before and after PSM.**

Parameter	Before PSM			After PSM		
	<5533.4	⩾5533.4	*P* value	<5533.4	⩾5533.4	*P* value
N	3995	611		602	602	602
Demographics						
Age, years	74.4 (63.4-82.9)	76.9 (68.2-83.7)	<0.001	77.7 (66.1-84.2)	76.9 (68.1-83.7)	0.984
Male, n (%)	2154 (53.9%)	282 (46.2%)	<0.001	279 (46.3%)	279 (46.3%)	1.000
Ethnicity, n (%)		0.001	0.001			0.526
White	2879 (72.1%)	470 (76.9%)		463 (76.9%)	461 (76.6%)	
Black	309 (7.7%)	23 (3.8%)		30 (5.0%)	23 (3.8%)	
Others	807 (20.2%)	118 (19.3%)		109 (18.1%)	118 (19.6%)	
Vital signs						
HR, beats/minute	84.5 (74.1-96.0)	88.2 (77.0-99.6)	<0.001	87.5 (77.3-98.8)	87.9 (76.8-99.2)	0.840
RR, times/minute	19.3 (16.8-22.3)	20.3 (17.6-23.2)	<0.001	20.2 (17.3-23.5)	20.2 (17.6-23.1)	0.876
SBP, mmHg	113.8 (104.6-126.0)	113.8 (104.6-126.0)	0.145	113.9 (103.4-125.6)	112.1 (103.5-125.7)	0.964
DBP, mmHg	57.1 (51.1-63.9)	55.7 (50.2-62.5)	0.009	55.3 (49.1-61.9)	55.6 (50.2-62.5)	0.219
Temperature, ℃	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.010	36.8 (36.4-37.2)	36.7 (36.3-37.1)	0.254
SpO2, %	97.3 (95.8-98.5)	97.0 (95.5-98.4)	0.157	97.3 (95.6-98.5)	97.0 (95.5-98.4)	0.474
Weight, kg	78.4 (65.0-94.3)	74.4 (61.0-90.0)	<0.001	73.0 (61.0-88.5)	74.4 (61.0-90.0)	0.560
Therapies, n (%)						
ACEI	1117 (28.0%)	149 (24.4%)	0.065	153 (25.4%)	147 (24.4%)	0.689
ARB	158 (4.0%)	25 (4.1%)	0.872	26 (4.3%)	25 (4.2%)	0.886
β-blocker	2454 (61.4%)	373 (61.0%)	0.858	373 (62.0%)	367 (61.0%)	0.722
Digoxin	411 (10.3%)	64 (10.5%)	0.888	85 (14.1%)	63 (10.5%)	0.053
Furosemide	2766 (69.2%)	424 (69.4%)	0.937	412 (68.4%)	416 (69.1%)	0.804
Statins	1274 (31.9%)	177 (29.0%)	0.148	158 (26.2%)	174 (28.9%)	0.302
Dialysis	426 (10.7%)	52 (8.5%)	0.104	86 (14.3%)	51 (8.5%)	0.001
Vasopressor	1042 (26.1%)	192 (31.4%)	0.008	171 (28.4%)	187 (31.1%)	0.313
Ventilation	1561 (39.1%)	318 (52.0%)	<0.001	306 (50.8%)	310 (51.5%)	0.818
Assisted circulation	259 (6.5%)	23 (3.8%)	0.009	21 (3.5%)	23 (3.8%)	0.759
Scores						
SOFA	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.556	5.0 (3.0-7.0)	5.0 (3.0-7.0)	0.405
SAPSII	40.0 (32.0-49.0)	45.0 (36.0-53.5)	<0.001	44.0 (35.0-53.0)	45.0 (36.0-53.0)	0.440

531   **Table 5.** Continued.

Parameter	Before PSM			After PSM		
	<5533.4	⩾5533.4	*P* value	<5533.4	⩾5533.4	*P* value
N	3995	611		602	602	
Laboratory events						
Hemoglobin, g/dl	11.0 (9.7-12.4)	10.7 (9.5-12.1)	0.008	10.7 (9.5-11.9)	10.7 (9.5-12.1)	0.290
Creatinine, mg/dl	1.2 (0.9-1.8)	1.2 (0.9-2.1)	0.250	1.3 (0.9-2.0)	1.2 (0.9-2.1)	0.160
BUN, mg/dl	26.0 (18.0-42.0)	30.0 (19.0-49.0)	<0.001	31.0 (20.0-49.0)	30.0 (19.0-48.0)	0.613
Glucose, mg/dl	134.0 (114.4-163.6)	145.5 (119.7-176.8)	<0.001	141.2 (117.1-180.3)	145.5 (119.6-176.2)	0.610
Sodium, mmol/L	139.0 (136.0-141.0)	138.0 (135.0-141.0)	<0.001	138.0 (135.0-141.0)	138.0 (135.0-141.0)	0.487
Potassium, mmol/L	4.2 (3.8-4.6)	4.2 (3.7-4.7)	0.575	4.2 (3.8-4.7)	4.2 (3.7-4.7)	0.634
Chloride, mmol/L	103.0 (100.0-107.0)	102.0 (98.0-107.0)	<0.001	103.0 (99.0-106.0)	102.0 (98.0-107.0)	0.377
Bicarbonate, mmol/L	25.0 (21.0-28.0)	24.0 (20.0-27.0)	<0.001	24.0 (20.0-27.0)	24.0 (20.0-27.0)	0.878
PT, second	14.3 (13.2-16.8)	14.4 (13.2-17.1)	0.245	14.4 (13.2-17.3)	14.4 (13.2-17.2)	0.846
APTT, second	31.8 (27.3-41.1)	31.6 (27.3-38.6)	0.329	31.3 (27.3-40.2)	31.7 (27.3-38.7)	0.920
Lactate, mmol/L	1.9 (1.3-2.9)	1.8 (1.3-2.8)	0.654	1.8 (1.3-3.0)	1.8 (1.3-2.8)	0.654
Albumin, g/dL	3.0 (2.6-3.4)	2.9 (2.5-3.3)	<0.001	2.8 (2.4-3.3)	2.9 (2.5-3.3)	0.255
Bilirubin, mg/dL	1.5 (0.6-3.1)	0.9 (0.4-2.5)	<0.001	1.1 (0.5-2.4)	0.9 (0.4-2.6)	0.282
ALT, IU/L	62.0 (22.0-309.0)	50.0 (21.0-242.7)	0.034	51.0 (21.0-225.8)	50.0 (21.0-248.5)	0.637
NT-proBNP, ng/ml	10.9 (4.6-18.6)	12.1 (5.1-19.8)	0.019			
cTnT, ng/mL	1.4 (0.1-2.9)	1.1 (0.1-2.5)	0.016	1.1 (0.1-2.8)	1.1 (0.1-2.5)	0.768
CI, L/min/m^2	2.8 (2.1-3.5)	2.8 (2.2-3.5)	0.309	2.8 (2.1-3.4)	2.8 (2.2-3.5)	0.938
Urine output, L	1.6 (0.9-2.5)	1.4 (0.8-2.1)	<0.001	1.4 (0.7-2.2)	1.4 (0.8-2.1)	0.522
Hospitalization type			0.002			0.238
Emergency, n (%)	3498 (87.6%)	564 (92.3%)		538 (89.4%)	555 (92.2%)	
Elective, n (%)	338 (8.5%)	29 (4.7%)		39 (6.5%)	29 (4.8%)	
First ICU admission			<0.001			0.004
CCU, n (%)	1098 (27.5%)	138 (22.6%)		143 (23.8%)	138 (22.9%)	
Length of ICU stay, h	93.0 (50.0-184.0)	109.0 (54.0-204.0)	0.003	118.5 (59.0-228.8)	109.0 (53.0-201.8)	0.128
Comorbidities, n (%)						
Hypertension	830 (20.8%)	107 (17.5%)	0.062	126 (20.9%)	106 (17.6%)	0.144
Hyperlipemia	1120 (28.0%)	140 (22.9%)	0.008	133 (22.1%)	138 (22.9%)	0.730
Diabetes mellitus	1449 (36.3%)	208 (34.0%)	0.285	205 (34.1%)	205 (34.1%)	1.000

532 **Table 5.** Continued.

Parameter	Before PSM			After PSM		
	<5533.4	≥5533.4	*P* value	<5533.4	≥5533.4	*P* value
N	3995	611		602	602	
Comorbidities, n (%)						
Atrial fibrillation	1783 (44.6%)	294 (48.1%)	0.107	281 (46.7%)	290 (48.2%)	0.603
AMI	301 (7.5%)	45 (7.4%)	0.882	39 (6.5%)	44 (7.3%)	0.570
VHD	402 (10.1%)	61 (10.0%)	0.952	88 (14.6%)	61 (10.1%)	0.018
Peripheral vascular	511 (12.8%)	66 (10.8%)	0.167	88 (14.6%)	64 (10.6%)	0.037
Pulmonary circulation	239 (6.0%)	53 (8.7%)	0.011	45 (7.5%)	52 (8.6%)	0.459
Pneumonia	1108 (27.7%)	242 (39.6%)	<0.001	235 (39.0%)	237 (39.4%)	0.906
COPD	188 (4.7%)	57 (9.3%)	<0.001	48 (8.0%)	53 (8.8%)	0.603
Liver diseases	214 (5.4%)	18 (2.9%)	0.011	20 (3.3%)	18 (3.0%)	0.742
Renal failure	982 (24.6%)	138 (22.6%)	0.284	162 (26.9%)	136 (22.6%)	0.083
Stroke	227 (5.7%)	23 (3.8%)	0.051	38 (6.3%)	23 (3.8%)	0.052
Hypothyroidism	461 (11.5%)	94 (15.4%)	0.007	97 (16.1%)	92 (15.3%)	0.692
Malignancy	209 (5.2%)	44 (7.2%)	0.047	31 (5.1%)	43 (7.1%)	0.150
Depression	303 (7.6%)	56 (9.2%)	0.175	50 (8.3%)	56 (9.3%)	0.542
30-day mortality	769 (19.2%)	204 (33.4%)	<0.001	150 (24.9%)	200 (33.2%)	0.002
90-day mortality	1120 (28.0%)	260 (42.6%)	<0.001	211 (35.0%)	253 (42.0%)	0.013
Hospital-day mortality	659 (16.5%)	172 (28.2%)	<0.001	135 (22.4%)	167 (27.7%)	0.033

Abbreviations: PSM, propensity score matching; HR, heart rate; RR, respiratory rate; SBP, systolic
blood pressure; DBP, diastolic blood pressure; SpO2, percutaneous oxygen saturation; ACEI,
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BUN, blood urea
nitrogen; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine
transaminase; cTnT, troponin T; NT-proBNP, N-terminal pro brain natriuretic peptide; CI, cardiac
index; SII, Systemic immune-inflammation index; CHF, congestive heart failure; AMI, acute
myocardial infarction; VHD, valvular heart disease; COPD, chronic obstructive pulmonary disease.
CCU, cardiac care unit.